BloodPressureHeartMeds.Net

TikoMed receives FDA Orphan Drug Designation for TM-400 to treat hematological cancers

June 08, 2017

In advanced prostate cancer cases, the testosterone driving the disease is converted into a more potent hormone that accelerates tumor growth. The standard treatment has been to deplete testosterone in the tumors, but they eventually become resistant to hormone depletion because they make their own androgens, or male hormones.

In the current study, UT Southwestern scientists analyzed prostate cancer cell lines, mouse models and fresh tumor tissue from patients. Their findings suggest that potential drug therapies need to target an enzyme responsible for initiating hormone production earlier in the process.

"This now suggests that a potential drug target is one step upstream in the pathway," said Dr. Sharifi. "This can be thought of as charting a map of the correct pathway. You have to figure out which way the river flows before you can block the river."

The findings also will help researchers develop accurate biomarkers of response and resistance to hormonal therapies, which eventually will help identify why and how prostate cancer tumors become resistant, he said.

Source: UT Southwestern Medical Center